February 7, 2018 / 1:13 PM / 5 months ago

BRIEF-Biogen Reports Top-Line Results From Phase 2b Study Of Natalizumab In Acute Ischemic Stroke

Feb 7 (Reuters) - Biogen Inc:

* BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE

* BIOGEN INC - PRIMARY AND SECONDARY EFFICACY ENDPOINTS WERE NOT MET IN ACTION 2 STUDY

* BIOGEN INC - FURTHER DEVELOPMENT OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE WILL NOT BE PURSUED

* BIOGEN INC - IN MIDDLE OF 2018, BIOGEN PLANS TO INITIATE A GLOBAL PHASE 3 STUDY OF BIIB093 IN INDIVIDUALS WITH LARGE HEMISPHERIC INFARCTION

* BIOGEN - IN PHASE 2A ACTION STUDY, SECONDARY, EXPLORATORY ENDPOINTS SUGGESTED NATALIZUMAB TREATMENT IMPROVED CLINICAL OUTCOMES VERSUS PLACEBO (ADDS DROPPED WORDS) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below